Why the COVID-19 variants might stretch the pandemic into 2024


Last week, New York provided a worrisome breakdown of what's happening in the Brazilian city of Manaus, whose population had previously been thought to have built up widespread protection against the virus last year, only to find itself experiencing another major outbreak. There are theories as to how this happened — community immunity being overestimated, waning antibody protection, the variant becoming more transmissible, or, perhaps most concerning, the virus adapting to evade antibodies.
Whatever the case, an increasing number of variants like the one in Brazil could theoretically push the end game back. Axios put it in slightly different terms — the current pandemic may be nearly over, but the variants could spark new ones.
Several vaccines have been shown to work well against the main coronavirus strain, and the more transmissible U.K. variant appears quite susceptible to them, as well, but the South African variant looks more resistant. And, New York notes, even a slight dip in efficacy could prevent "population-scale protection through vaccination alone."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The New York Times, however, explains that reports on vaccine efficacy often don't tell the whole story. Scientifically speaking, vaccine research considers any transmission a failure, but that may not be the most important thing. Novavax and Johnson & Johnson provided data that showed their vaccine candidates did not stop infections in South Africa as well as they did elsewhere, but they were still very successful at preventing severe disease, hospitalizations, and death. That suggests a possible scenario in which vaccines reduce the coronavirus to a much milder pathogen.
But that still may not be enough globally, per New York. Even if vaccines significantly reduce the worst COVID-19 outcomes, the world's poorer countries are not estimated to reach mass immunization until 2024, so while the tide may turn more quickly in the United States, the global pandemic could still be ongoing for years to come, especially if variants impede natural herd immunity. Read more at New York, Axios, and The New York Times.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The new Gwada negative blood type
Under The Radar Rare discovery means a woman is the only person on the planet who's compatible solely with herself
-
June 29 editorial cartoons
Cartoons Sunday's political cartoons include the AI genie, Iran saving face, and bad language bombs
-
A tall ship adventure in the Mediterranean
The Week Recommends Sailing aboard this schooner and exploring Portugal, Spain and Monaco is a 'magical' experience
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia